GLP-1 Medications: The Medical Weight Loss Revolution Explained

Few developments in modern medicine have generated as much attention — or as much confusion — as GLP-1 receptor agonists. Originally developed as diabetes medications, drugs like semaglutide and liraglutide have transformed how the medical community thinks about obesity. As a physician overseeing weight management programmes at Zainee's Aesthetics, I want to cut through the hype and give you the facts: what these medications do, who they work for, what they don't do, and what responsible medical weight loss looks like in practice.

What is GLP-1?

GLP-1 (Glucagon-Like Peptide-1) is a hormone naturally produced in the intestine in response to food intake. It performs several important functions:

• Stimulates insulin secretion from the pancreas (glucose-dependent)
• Suppresses glucagon (the hormone that raises blood sugar)
• Slows gastric emptying — food moves more slowly from the stomach to the intestine
• Acts on the hypothalamus in the brain to reduce appetite and increase satiety signals

In people with obesity, GLP-1 secretion is often blunted after meals. GLP-1 receptor agonist medications mimic and amplify these effects — but last much longer than the body's natural GLP-1 (which is degraded within minutes).

How Do They Cause Weight Loss?

The weight loss effect of GLP-1 agonists is primarily driven by appetite reduction and altered food reward signalling in the brain. Patients consistently report:

• Feeling full after much smaller meals
• Reduced cravings — particularly for high-calorie, processed foods
• "Food noise" (the persistent mental preoccupation with food) significantly diminishes
• Reduced compulsive eating behaviours

This is not simply "feeling less hungry." Brain imaging studies show that GLP-1 agonists directly reduce activity in the reward centres of the brain that drive overconsumption. For many patients, this represents the first time in their lives that food has not occupied a disproportionate amount of cognitive space — a genuinely life-changing experience.

What Does the Evidence Show?

The clinical trial data for GLP-1 agonists in obesity is remarkably strong:

• The STEP 1 trial (semaglutide 2.4mg weekly) showed an average body weight reduction of 14.9% at 68 weeks in non-diabetic patients with obesity — far exceeding any previous pharmacological intervention
• The SURMOUNT-1 trial (tirzepatide, a dual GLP-1/GIP agonist) showed weight reductions of up to 22.5% — approaching the results of bariatric surgery
• Cardiovascular outcome trials show significant reduction in major cardiac events in high-risk patients
• Significant improvements in blood pressure, lipid profiles, sleep apnoea severity, and joint pain are consistently reported

Who is a Candidate?

In our programme at Zainee's Aesthetics, we consider GLP-1 therapy for patients who meet the following criteria:

• BMI ≥ 30 (obese), or BMI ≥ 27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, sleep apnoea, dyslipidaemia)
• Have attempted lifestyle modification (diet + exercise) without achieving sustainable weight loss
• No personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
• No history of pancreatitis
• Not pregnant or breastfeeding

What Responsible Medical Weight Loss Looks Like

I am concerned by the proliferation of online prescriptions for GLP-1 medications without proper clinical oversight. At our clinic, we do not prescribe these medications in isolation. Our programme includes:

1. Full clinical assessment — history, examination, baseline bloods (HbA1c, lipids, LFTs, TFTs, kidney function)
2. Personalised dosing schedule — we start at the lowest effective dose and titrate slowly to minimise side effects
3. Nutritional support — patients on GLP-1 therapy eat significantly less, making nutritional density critical to prevent deficiency
4. Exercise guidance — maintaining muscle mass during rapid weight loss requires structured resistance training
5. Monthly monitoring — weight, blood pressure, bloods at intervals, and medication review

Common Side Effects and How We Manage Them

The most common side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation — and occur most frequently during dose escalation. In our experience, these are significantly reduced by:

• Starting at a very low dose (0.25mg weekly for semaglutide) and escalating slowly
• Eating smaller, low-fat meals
• Avoiding eating too quickly
• Staying well hydrated

For most patients, nausea resolves within 4–8 weeks as the body adjusts.

What Happens If You Stop?

This is the most important question — and one that requires honest discussion. Studies consistently show that weight regain occurs when GLP-1 medications are stopped without sustained lifestyle changes in place. These medications correct a physiological imbalance; they do not cure it. Long-term or indefinite use is appropriate for many patients, in the same way that antihypertensives are used long-term to manage blood pressure.

Patients who use the period of reduced appetite to build genuine dietary and exercise habits — with our support — have the best long-term outcomes even after discontinuation.